Tucatinib/Tucatinib belongs to which generation of targeted drugs

Tucatinib is an oral small molecule targeted drug that is a HER2 (human epidermal growth factor receptor 2) targeted inhibitor. In the development history of HER2-targeted drugs, tucatinib is classified as a third-generation small molecule targeted drug. Its research and development background stems from improving the clinical limitations of early first- and second-generation HER2 inhibitors. First-generation HER2 inhibitors such as Trastuzumab are monoclonal antibodies that block signaling pathways by binding to the external structure of the receptor. However, they have insufficient efficacy in patients with brain metastasis and drug resistance. Second-generation HER2 inhibitors such as lapatinib are dual-target tyrosine kinase inhibitors. Although they are convenient to take orally, they still have problems such as insufficient selectivity, cardiotoxicity, or a high incidence of drug resistance.

The third generation of tucatinib is characterized by its high selectivity and reversibility, specifically targetingHER2 tyrosine kinase, but has a weak inhibitory effect on other receptors such as EGFR, thereby significantly reducing non-specific toxicity while maintaining efficacy. This high selectivity gives tucatinib a unique advantage in the treatment of HER2-positive advanced breast cancer, especially in patients with brain metastases. Clinical studies have shown that tucatinib can significantly prolong progression-free survival (PFS) and improve the overall response rate. It also has certain penetration and inhibitory effects on brain metastases, which is difficult to achieve with early HER2 inhibitors.

In addition, tucatinib, as a third-generation targeted drug, is often used in combination with otherHER2-targeted antibodies or chemotherapy drugs to exert a synergistic effect and improve the efficacy of drug-resistant or relapsed patients. Its oral delivery method also improves patient compliance, making long-term maintenance treatment more feasible. By precisely inhibiting the HER2 signaling pathway, tucatinib not only improves tumor control, but also shows clinical advantages in reducing severe side effects, providing an innovative treatment option for patients with advanced HER2-positive breast cancer, marking the entry of HER2-targeted drugs into a stage of higher precision and safety.

Reference materials:https://www.tukysa.com/